^
    29d
    SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (clinicaltrials.gov)
    P3, N=332, Active, not recruiting, Camurus AB | Trial completion date: Dec 2027 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    lanreotide prolonged-release subcutaneous • Oclaiz (octreotide subcutaneous depot) • octreotide acetate
    4ms
    Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov)
    P3, N=274, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lanreotide prolonged-release subcutaneous • Somatuline LA (lanreotide suspension intramuscular)
    5ms
    The Combination Therapy of Pasireotide LAR Plus Pegvisomant and Cabergoline Relieved Acromegaly-Related Headache in a Female Patient with AIP-Mutated Acromegaly: A Case Report. (PubMed, Endocr Metab Immune Disord Drug Targets)
    This case report highlights the potential benefits of pasireotide in the treatment of refractory headaches, particularly when combined with pegvisomant.  .
    Journal
    |
    SSTR (Somatostatin Receptor) • IGF1 (Insulin-like growth factor 1)
    |
    lanreotide prolonged-release subcutaneous • Signifor LAR (pasireotide long acting release)
    5ms
    RIALTO: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (clinicaltrials.gov)
    P3, N=166, Recruiting, Grupo Espanol de Tumores Neuroendocrinos | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lutathera (lutetium Lu 177 dotatate) • lanreotide prolonged-release subcutaneous • octreotide acetate
    7ms
    Heterozygous Men1(+/T) Knockout Mice Do Not Develop Bronchopulmonary Neuroendocrine Hyperplasia or Neoplasia but Bronchial Adenocarcinoma. (PubMed, Adv Respir Med)
    Heterozygous Men1(+/T) knockout mice do not develop bronchopulmonary NEN or precursor lesions, but pulmonary adenocarcinoma. This surprising result needs to be investigated in more detail.
    Preclinical • Journal
    |
    SYP (Synaptophysin)
    |
    lanreotide prolonged-release subcutaneous
    9ms
    RIALTO: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (clinicaltrials.gov)
    P3, N=166, Not yet recruiting, Grupo Espanol de Tumores Neuroendocrinos
    New P3 trial
    |
    Lutathera (lutetium Lu 177 dotatate) • lanreotide prolonged-release subcutaneous • octreotide acetate
    9ms
    LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, Antonio Fojo | Recruiting --> Active, not recruiting | N=40 --> 10 | Trial completion date: Dec 2023 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Mar 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    lanreotide prolonged-release subcutaneous
    10ms
    Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET). (PubMed, J Neuroendocrinol)
    We conclude that immune checkpoint blockade had low activity in unselected patients with grade 1 and 2 GEP-NETs. Further study of strategies to reduce Treg activation or enhance effector memory activation during immunotherapy is warranted.
    P1/2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • lanreotide prolonged-release subcutaneous
    10ms
    Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov)
    P3, N=274, Not yet recruiting, SWOG Cancer Research Network
    New P3 trial
    |
    lanreotide prolonged-release subcutaneous • Somatuline LA (lanreotide suspension intramuscular)
    10ms
    Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China (clinicaltrials.gov)
    P=N/A, N=129, Completed, Ipsen | Active, not recruiting --> Completed
    Trial completion • Real-world evidence
    |
    IGF1 (Insulin-like growth factor 1)
    |
    lanreotide prolonged-release subcutaneous
    10ms
    AIM-NETs: Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (clinicaltrials.gov)
    P=N/A, N=71, Completed, Asan Medical Center | Recruiting --> Completed
    Trial completion
    |
    lanreotide prolonged-release subcutaneous
    11ms
    OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov)
    P1, N=20, Terminated, Debiopharm International SA | Active, not recruiting --> Terminated; The recruitment was halted for strategic reasons
    Trial termination
    |
    IGF1 (Insulin-like growth factor 1)
    |
    lanreotide prolonged-release subcutaneous • octreotide 3-month extended release (Debio 4126) • octreotide acetate